Scancell Share Discussion Threads

[marcusl2] 27/3/2023 11:06

Wigw, hopefully we get further positive updates in April.

[wigwammer] 27/3/2023 10:20

Great news for that patient, Marcus. Re is it modi1 related? Bear in mind there is a maximum of only 2 male patients on the trial as of the last update, one potentially in H&N, one potentially in RCC.

[marcusl2] 27/3/2023 08:49

It would also be nice to get a Car T deal for SC129

There was another post 18 days ago on McM. It would be nice if this was referring to Modi-1 but there were no further details.

"my husband has cancer also and has been trying new vaccine and we got great news today that his cancer has shrunk immensely so another cancer breakthrough"

[inanaco] 27/3/2023 05:25

update to Chesters Post

Direct View of resected cancer

MAB2811 ...

TCB antibody .... singular

Taxation under Patent Box

Regulatory changes to suit vaccines by the MHRA and FDA 23/24

Tax Changes to suit R & D April 2023

[panama7] 26/3/2023 22:03

40m Covid Vaccine doses due to expire in East Africa and there are posters here and on the other channel who believe Scancell will get a deal for Covidity. I'm afraid some of you really need to get off the MSM and broaden your research.

[panama7] 26/3/2023 19:44

Ruck, we are all being fooled and manipulated but some of us have woken up to that fact. Worth checking out " Operation Mockingbird "

[ruckrover] 26/3/2023 12:36

P7,
I was fooled and manipulated for 40 odd years and I quite accept the possibility I am still fooled and manipulated but by a different set of people.

You say
""After all these are the same people that have followed a share for 12 years for it to be the same price it was 12 years ago.""

I wish! Share price on 26/03/2013 39.5p. Now wouldn't that be nice?

[panama7] 26/3/2023 11:36

Fast Lane, no matter how many Truth Bombs you drop on here there are far toom many big ego's , Truth deniers and Cowards to accept they could possibly be wrong about anything and that they have been manipulated. After all these are the same people that have followed a share for 12 years for it to be the same price it was 12 years ago.

[fast lane] 25/3/2023 12:26

End Bottom for humanity.

In my opinion.

O.M.G.



Australian government biodistribution data

[markingtime] 25/3/2023 10:47

Apparently she has a double bottom. Who knew? :-))

[the real lozan] 25/3/2023 09:09

Not as big as some on this forum,
And certainly not as big as most on the other forum

[dominiccummings] 24/3/2023 22:20

Has she got a nice pair on her?

[inanaco] 24/3/2023 20:07

The FDA’s Oncology Center of Excellence has been a bright spot within the agency in terms of speeding new treatments to patients. That flexibility was on full display this morning as FDA released new draft guidance spelling out exactly how oncology drug developers can fulfill both the accelerated and full approval’s requirements with just a single randomized controlled trial.

While Congress recently passed legislation that will allow FDA to require confirmatory trials to be recruiting and ongoing prior to granting an accelerated approval, the agency is now making clear that the initial trial used to win the AA, if designed appropriately, can also serve as the trial for converting the accelerated approval into a full approval.

OCE officials discussed this concept of a single trial in the NEJM last October, explaining: “AA could be granted on the basis of a planned interim analysis of overall response rate, and traditional approval granted on the basis of clinical benefit (usually improvement in overall survival) at the trial’s conclusion.”

But the design of that trial must be precise as FDA says in today’s draft guidance that it must be “powered for the longer-term clinical endpoint with follow-up in the same trial to verify clinical benefit,” and should ensure that the accelerated nod doesn’t inadvertently introduce bias.

So what are the benefits of such an approach? FDA points to “a more thorough safety assessment and earlier definitive evidence of the benefit–risk balance,” as well as reducing the risk of halting the drug’s development too early, or one with a limited overall response rate that may end up as an OS improvement. Moreover, the randomized trial could be conducted in patients in an earlier treatment setting, the draft adds, so the drug would reach more patients in whom efficacy might be greater.

As far as logistics, the draft notes, “The trial sample size should be chosen so that it has adequate power to detect a clinically meaningful and statistically significant improvement in both the endpoints for accelerated approval (e.g., response rate) and verification of clinical benefit (e.g., PFS or OS).”

Because the treatment landscape for cancer is constantly in flux, FDA explains that sponsors should discuss any updates with the agency, which could lead to deferred accelerated submissions until the results for a traditional approval are available. That may be a sticking point for industry, which if they run one trial and a confirmatory follow-up, can make money on the AA while the follow-up trial is ongoing.

FDA also makes clear, as with the passage of the omnibus at the end of last year stipulated, that the agency may “require, as appropriate, that studies intended to verify clinical benefit be underway prior to approval, or within a specified time period after the date of approval, of the applicable product.”

Such confirmatory trials must be carried out with “due diligence,” the agency notes, as the OCE officials previously explained in the NEJM how the median time for oncology accelerated approvals to either confirm benefit or fail was longer if the confirmatory trial was initiated after the approval. The guidance also does not discuss the expedited ways in which FDA can pull AAs if they fail those confirmatory trials, which was also included in the omnibus.

Outside of oncology, Eisai and Biogen’s Alzheimer’s drug Leqembi (lecanemab) recently employed this strategy, relaying on the same trial’s results to win accelerated approval in January, with an expected full approval sometime before its PDUFA date of July 6.

[inanaco] 24/3/2023 18:49

this is the evidence that setting up the right T cell profile by using amplivant produced the desired outcome so how you activate the t cells is absolutely critical
this is early work with adjuvants but you can see the effect of the vaccine same peptide ............. but some dreadful results in the mouse model using different adjuvants


Furthermore the cytokine phenotype of these self antigen specific responses can be dramatically polarised when
combined with different adjuvant combinations and costimulation resulting in a change in tumour targeting ability

[inanaco] 24/3/2023 16:27

the CD4 T cell is a general ........... it plasticity allows it to shape change

it controls an immune response depending on how its activated .. it will have a profile thats given by what cytokines it delivers these instruct other immune effector CD 8 t cells NK cells and other even activating B cells to produce antibodies

others will activate as Suppressor T cells to calm down an immune response ...

they rarely do any killing ........ only at the extreme end of infections

but ""Citrullinated proteins"" are so immunogenic they drive the CD4 T cell to acquire cytotoxic capability now the General has taken control ..

the effects you are already seeing ...........

they are Th1 proinflammatory Killer Cd4 T cells

Lindy has activated the most potent t cell available ....after all it is a General

and just how complicated the process is .........

[capt bligh] 24/3/2023 16:00

Am I the only investor here that would like someone clever to write a "Scancell for dummies" article... while I semi-absob much of the science data and (a special thanks to Ianaco here)... what would be useful would be a digest using perhaps military ( but whatever) imagery to expain the various challenges, resources and successes over our varius platforms and their stengths relative to other DNA oncolological strategies that we know about. When talking to fiends I am always flumoxed trying to explain Scancell.

[inanaco] 24/3/2023 13:35

a reminder


inanaco - 09 Mar 2023 - 09:25:29 - 56973 of 57040 Using immunology to fight cancer. - SCLP
Meanwhile Back in Camp Damp ... headed by new recruit Ruck .. the market gave him 5 shares at 16.5p towards his 15p estimated Target with his last investment around that level of 6500 shares, Ruck had a celebration of a whole boiled egg rather than normally sharing with his wife, as a milestone was achieved ... Nana commented HVO might get there first ...

[panama7] 24/3/2023 11:32

Families of the bereaved and severely disabled launch class action lawsuit against AZ for the harms caused by the Vaccine. With Doctors and Politicians calling for a cessation of mRNA jabs in S.Africa, Australia and Israel in the last couple of days and States in the U.S banning mRNA what price for safe and effective traditional Vaccines , surprised Scancell share price is still in the doldrums. The question the majority of you have to ask yourself will Scancell's share price explode before your immune systems.

[inanaco] 24/3/2023 11:01

The Race to 15p ...................

won by Ivy with HVO ....

[inanaco] 24/3/2023 10:52

serrita absolutely

the trial will Identify that for sure

[inanaco] 24/3/2023 10:50

i will always give examples .... Biontech


"""however, in this study the outgrowth of B2M deficient tumor cells in one patient demonstrates the complexity of the TME and the selective pressures that drive resistance to therapy."""

so patient X has received prior treatment and we have NO idea if selective pressure has been applied to patient x cancer and what that entails ....







In a study performed by Sahin et al. the use of an RNA vaccine encoding neoantigens was explored (174) in melanoma patients. In this study neoantigens were identified by comparative exome analysis in tumors from thirteen patients with stage III and IV melanoma. Mutations were selected for incorporation into the vaccine based firstly on the predicted binding score for HLA class II and secondly based on the predicted binding score for HLA class I. For each patient two synthetic RNAs were synthesized incorporating the identified mutations. The RNA vaccine was produced within 68 days (range 49 to 102 days), following analytical testing they were released within 103 days (range 89 to 160 days). RNA vaccines work in a similar way to the long peptide vaccines, the RNA is translated into protein which is then processed into long peptides by APCs, these peptides are then loaded onto MHC class I or class II molecules and presented on the cell surface to prime and activate T cells. This study demonstrated the clinical feasibility and safety of RNA neo-epitope vaccines. In this study 8/13 patients had no tumors develop during the monitoring period and neoantigen specific T cells could be detected in the peripheral blood of these patients. The use of many neoantigen epitopes in a vaccine reduces the risk of single antigen loss variants (175), however, in this study the outgrowth of B2M deficient tumor cells in one patient demonstrates the complexity of the TME and the selective pressures that drive resistance to therapy.

[serratia] 24/3/2023 10:45

As Modi is directed at modified amino acids created during tumour degeneration is it likely to be effective against the juvenile cells thrown off when a tumour spreads ?